{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:03:15Z","timestamp":1757617395720,"version":"3.44.0"},"reference-count":40,"publisher":"American Society of Consultant Pharmacists","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:p><jats:bold>Background<\/jats:bold> Older adults are at increased risk for opioid-related harm due to decreased drug metabolism and elimination, polypharmacy, and comorbid conditions. The ONE (Opioid and Naloxone Education) Program is a pharmacy-based opioid risk mitigation initiative that employs\n evidence-based patient screening to identify risk of opioid-use-disorder (OUD) and opioid overdose (OD). Based on screening results, pharmacists provide patient-specific education and interventions.  <jats:bold>Objective<\/jats:bold> To compare the risk of OUD, OD, and the opioid harm reduction\n interventions provided to adults aged 65 and older to those under 65 recieving opioid medications.  <jats:bold>Design<\/jats:bold> The screening tool used in this study is a paper-based, patient-facing instrument intended to be completed by the patient. Pharmacists recommend patients to complete\n the screening tool and participate when presenting an opioid prescription to be filled. However, completing the screening tool is voluntary for the patient.  <jats:bold>Setting<\/jats:bold> The ONE Program invited all registered pharmacists in the state to participate in a free three-hour continuing\n education (CE) program, offered live or online. The training consisted of education including but not limited to risks associated with opioids and accidental overdose, the role of naloxone, and the use and interpretation of the opioid risk screening tool. The program began in 2018 in North\n Dakota and now spans over 75 community pharmacies across the state.  <jats:bold>Methods<\/jats:bold> Patient demographics, opioid risk screening results, and pharmacist-delivered interventions were analyzed from 2022 to 2023. Statistical analysis and age stratification were conducted on 15,025\n screenings to evaluate OUD risk, OD risk, and delivered interventions. The North Dakota State University Institutional Review Board approved the methods and research design of this study (IRB0003838).  <jats:bold>Results<\/jats:bold> Patients aged 65 and older had a 36% higher risk of OD, while\n those under 65 had a 51% higher risk of developing OUD. The older age group received a statistically significant higher proportion of naloxone education and dispensed naloxone from the pharmacy. Concurrent use of benzodiazepines and muscle-relaxants was significantly higher in the younger\n age group; however, the 65 and older age group reported taking multiple opioids nearly twice as frequently as those under 65.  <jats:bold>Conclusion<\/jats:bold> A comparison of opioid use, opioid risk stratification, and interventions for patients under 65 and 65 and older showed statistically\n significant findings. Community pharmacy-based opioid risk screening offers an innovative approach to identifying high-risk patients and delivering tailored interventions directed to opioid-harm reduction.<\/jats:p>","DOI":"10.4140\/tcp.n.2025.325","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T04:30:26Z","timestamp":1754541026000},"page":"325-333","source":"Crossref","is-referenced-by-count":0,"title":["Community Pharmacy Opioid Risk Screening Assessments: Comparing older adults (65+) to those under 65"],"prefix":"10.4140","volume":"40","author":[{"given":"Oliver","family":"Frenzel","sequence":"first","affiliation":[{"name":"North Dakota State University, Fargo, North Dakota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayne","family":"Steig","sequence":"additional","affiliation":[{"name":"North Dakota State University, Fargo, North Dakota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabell","family":"Delgado","sequence":"additional","affiliation":[{"name":"North Dakota State University, Fargo, North Dakota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Eukel","sequence":"additional","affiliation":[{"name":"North Dakota State University, Fargo, North Dakota."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40266-021-00893-z","article-title":"Problematic Opioid Use Among Older Adults: Epidemiology, Adverse Outcomes and Treatment Considerations.","volume":"38","year":"2021","journal-title":"Drugs Aging."},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamapsychiatry.2022.5159","article-title":"Twenty-year trends in drug overdose fatalities among older adults in the US.","volume":"80","year":"2023","journal-title":"JAMA Psychiatry."},{"journal-title":"Federal Practitioner.","year":"2024","key":"ref3"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/ACO.0000000000000814","article-title":"Pharmacodynamics and pharmacokinetics in older adults.","volume":"33","year":"2020","journal-title":"Curr Opin Anaesthesiol."},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.amepre.2021.01.010","article-title":"Trends in Opioid Use Disorder Among Older Adults: Analyzing Medicare Data, 2013\u20132018.","volume":"60","year":"2021","journal-title":"Am J Prev Med."},{"issue":"1","key":"ref6","first-page":"33","article-title":"National estimates of exposure to prescription drugs with addiction potential in community-dwelling elders.","volume":"26","year":"2005","journal-title":"Subst Abus."},{"key":"ref7","first-page":"8596","article-title":"Screening tools for detecting problematic opioid use and potential application to community pharmacy practice: a review.","volume":"8","year":"2019","journal-title":"Integr Pharm Res Pract."},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.sapharm.2023.05.003","article-title":"A scoping literature review of pharmacy-based opioid misuse screening and brief interventions.","volume":"19","year":"2023","journal-title":"Res Social Adm Pharm."},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1331\/JAPhA.2014.13101","article-title":"Pharmacists\u2019 role in addressing opioid abuse, addiction, and diversion.","volume":"54","year":"2014","journal-title":"J Am Pharm Assoc."},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajhp\/zxy089","article-title":"The opioid crisis: origins, trends, policies, and the roles of pharmacists.","volume":"76","year":"2019","journal-title":"Am J Health Syst Pharm."},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/JAN.0000000000000488","article-title":"Prescription opioid misuse in older adult surgical patients: epidemiology, prevention, and clinical implications.","volume":"33","year":"2022","journal-title":"J Addict Nurs."},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.japh.2019.09.003","article-title":"Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.","volume":"60","year":"2020","journal-title":"J Am Pharm Assoc."},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.sapharm.2018.07.011","article-title":"Moving opioid misuse prevention upstream: a pilot study of community pharmacists screening for opioid misuse risk.","volume":"15","year":"2019","journal-title":"Res Social Adm Pharm."},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","article-title":"Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool.","volume":"6","year":"2005","journal-title":"Pain Medicine."},{"issue":"4","key":"ref15","first-page":"318","volume":"116","year":"2019","journal-title":"Mo Med."},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"e051663","DOI":"10.1136\/bmjopen-2021-051663","article-title":"Predicting opioid-induced oversedation in hospitalised patients: a multicentre observational study.","volume":"11","year":"2021","journal-title":"BMJ Open."},{"issue":"13","key":"ref17","first-page":"e1432","article-title":"Comparative risk of opioid overdose with concomitant use of prescription opioids and skeletal muscle relaxants.","volume":"99","year":"2022","journal-title":"Neurology."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"109196","DOI":"10.1016\/j.drugalcdep.2021.109196","article-title":"Alcohol-involved overdose deaths in US veterans.","volume":"230","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/pme.12480","article-title":"Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients.","volume":"15","year":"2014","journal-title":"Pain Med."},{"issue":"1","key":"ref20","first-page":"85","article-title":"Cohort study of the impact of high-dose opioid analgesics on overdose mortality.","volume":"17","year":"2016","journal-title":"Pain Med."},{"key":"ref21","article-title":"Notes from the field: antihistamine positivity and involvement in drug overdose deaths \u2014 44 jurisdictions, United States, 2019\u20132020.","volume":"71","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"ref22","first-page":"j760","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis.","volume":"356","year":"2017","journal-title":"BMJ."},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"e024086","DOI":"10.1136\/bmjopen-2018-024086","article-title":"Risk factors for opioid-induced respiratory depression in surgical patients: a systematic review and meta-analyses.","volume":"8","year":"2018","journal-title":"BMJ Open."},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/CEH.0000000000000233","article-title":"Changes in pharmacists\u2019 perceptions after a training in opioid misuse and accidental overdose prevention.","volume":"39","year":"2019","journal-title":"J Contin Educ Health Prof."},{"issue":"43","key":"ref25","first-page":"1051","article-title":"Longitudinal evaluation of pharmacists\u2019 social distance preference and attitudes towards patients with opioid misuse following an educational training program.","year":"2022","journal-title":"Subst Abus."},{"year":"2024","key":"ref26"},{"year":"2024","key":"ref27"},{"year":"2024","key":"ref28"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.sapharm.2019.11.016","article-title":"Program evaluation of the Opioid and Naloxone Education (ONE Rx) program using the RE-AIM model.","volume":"16","year":"2020","journal-title":"Res Social Adm Pharm."},{"key":"ref30","first-page":"1","article-title":"Patient acceptance of naloxone resulting from targeted intervention from community pharmacists to prevent opioid misuse and accidental overdose.","year":"2020","journal-title":"Subst Abus."},{"issue":"17","key":"ref31","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.3390\/ijerph20176628","article-title":"Implementation of a pharmacy follow-up program for dispensed opioid medications.","volume":"20","year":"2023","journal-title":"Int J Environ Res Public Health."},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1176\/appi.ps.202100592","article-title":"Improving community pharmacist\u2013delivered care for patients with psychiatric disorders filling an opioid prescription.","volume":"73","year":"2022","journal-title":"Psychiatric Services."},{"key":"ref33","first-page":"73","article-title":"Treatment for opioid use disorder: population estimates \u2014 United States, 2022.","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"100175","DOI":"10.1016\/j.focus.2023.100175","article-title":"Burden of chronic and heavy opioid use among elderly community dwellers in the U.S.","volume":"3","year":"2024","journal-title":"AJPM Focus."},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"e0282536","DOI":"10.1371\/journal.pone.0282536","article-title":"Prevalence and correlates of prescription opioid use among US adults, 2019\u20132020.","volume":"18","year":"2023","journal-title":"PLoS One."},{"journal-title":"NCHS Data Brief,","article-title":"Chronic pain and high-impact chronic pain in U.S. adults, 2023.","year":"2024","key":"ref36"},{"year":"2024","key":"ref37"},{"key":"ref38","article-title":"CDC Clinical Practice Guideline for Prescribing Opioids for Pain \u2014 United States, 2022.","volume":"71","year":"2022","journal-title":"MMWR Recomm Rep."},{"key":"ref39","article-title":"Vital Signs: Pharmacy-based naloxone dispensing \u2014 United States, 2012\u20132018.","volume":"68","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep."},{"volume-title":"Substance Use Disorders: Age-Adjusted Psychiatric Treatment for the Older Patient.","year":"2024","key":"ref40"}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2025\/00000040\/00000008\/art00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:34:38Z","timestamp":1757133278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2025.325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"alternative-id":["2639-9636(20250801)40:8L.325;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2025.325","relation":{},"ISSN":["2639-9636"],"issn-type":[{"type":"print","value":"2639-9636"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}